CD33和集群蛋白在生物物理和遗传上相互作用,调节阿尔茨海默氏症风险
bioRxiv : the preprint server for biology
|August 6, 2025
概括
在CD33中非编码变体通过影响微质功能来改变阿尔茨海默病 (AD) 风险. 上调的CD33与AD蛋白相互作用,抑制粉样质斑块的去除,增加AD风险.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 免疫学 免疫学 免疫学
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,具有复杂的遗传基础.
- 编码酸结合受体的CD33基因与AD风险有关.
- 微质细胞在大脑稳定和AD病变发生过程中发挥着至关重要的作用,包括粉样β (Aβ) 斑块清除.
研究的目的:
- 研究CD33影响阿尔茨海默病风险的结构,功能和遗传机制.
- 阐明CD33异型的作用及其与AD相关蛋白的相互作用在疾病发病过程中的作用.
- 探索CD33和CLU基因变异的潜力,以实现个性化的AD疗法.
主要方法:
- 对CD33受体的结构和功能研究.
- 基因分析,包括人类大脑表达量的特征位点 (eQTL) 和因果调解分析.
- 研究CD33与AD相关蛋白质的相互作用,如集群蛋白和Aβ.
主要成果:
- 非编码的AD风险等位基因对全长CD33M异型进行上调,该异型基因形成二次体,并与集群蛋白和Aβ相互作用.
- CD33 M二分化抑制了粉样质斑块的微细胞化,损害了保护功能.
- 克鲁和CD33基因型之间的遗传相互作用调节AD表型,建议个性化治疗策略.
结论:
- CD33 M通过抑制粉样斑块的微质清除,在AD病变发生过程中发挥着关键作用.
- CD33和CLU的遗传变异为AD风险分层和个性化治疗方法提供了潜在的生物标志物.
- 发现了新的可溶性CD33M片段,为了解CD33生物学的新途径.
相关概念视频
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262


